Jongwon Yoon

Jongwon Yoon

Auto-generated profile, based on publicly available information

Jongwon Yoon

R&D Center, GeneMatrix, Inc., Seongnam-si, Gyeonggi-do, Republic of Korea

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2021 in Virology
Verified
Journal Article
Closed access
HOHyun-Seok Oh
Hyun-Seok Oh
JYJong Won Yoon
Jong Won Yoon
SLSanghyun Lee
Sanghyun Lee
SKSoo-Ok Kim
Soo-Ok Kim
SHSun Pyo Hong
Sun Pyo Hong

20 October 2025 in bioRxiv
Verified
Preprint
Open access
AGAmalie Grenov
Amalie Grenov
JYJongwon Yoon
Jongwon Yoon
DSDaniel M. Snell
Daniel M. Snell
AMAnna Mikolajczak
Anna Mikolajczak
HWHao Wang
Hao Wang
CVCarola G. Vinuesa
Carola G. Vinuesa
Summary: Anti-CD19 chimeric antigen receptor (CAR)-T therapy induces profound remissions in lupus by depleting B cells, challenging the longstanding view that treatment-resistant disease is sustained by long-lived plasma cells. Additionally, emerging relapses highlight the need to understand how pathogenic autoantibodies arise. Using molecular antibody tagging in mice with human monogenic lupus variants, we reveal that autoantibody-producing cell cohorts are long-lived but plasma cells are short-lived, requiring continuous replenishment from proliferating precursors. The spleen acts as a major plasma cell reservoir, with perivascular localization conserved in mice and lupus patients. Relapse after anti-CD19 CAR-T occurred through newly-generated B cells rather than treatment-resistant clones. Plasma cell depletion by anti-BCMA CAR-T failed to eliminate some precursors that become autoantibody-secreting. These findings demonstrate that continuous B cell-to-plasma cell differentiation, not intrinsic plasma cell longevity, sustains pathogenic antibody responses in lupus, supporting a potential benefit of adjunctive therapies after CAR-T, particularly in genetically predisposed patients.